Olodanrigan - Novartis

Alternative Names: EMA401

Latest Information Update: 04 Nov 2018

Price : $50 ^*

* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

Originator Spinifex Pharmaceuticals
Developer Novartis
Class Analgesics; Small molecules; Tetrahydroisoquinolines
Mechanism of Action Angiotensin type 2 receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase II Diabetic neuropathies; Neuropathic pain; Postherpetic neuralgia

Most Recent Events

28 Mar 2018 No recent reports of development identified for phase-I development in Neuropathic-pain(In volunteers) in Australia (PO, Tablet)
28 Mar 2018 No recent reports of development identified for phase-I development in Postherpetic-neuralgia(In volunteers) in Australia (PO, Tablet)
14 Mar 2018 Phase-II EMPADINE trials in Diabetic neuropathies (In adults, In the elderly) in Austria, Denmark, Finland, Hungary, Norway, Spain, Slovakia, United Kingdom (PO) (NCT03297294)

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Login with a username/password associated to an account with a valid subscription
Contact your organization’s admin about adding this content to your AdisInsight subscription
Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Welcome to AdisInsight